Novartis AG
STABLE AND SOLUBLE ANTIBODIES INHIBITING VEGF
Last updated:
Abstract:
The present invention relates to soluble and stable anti-VEGF imunobinders comprising CDRs from rabbit monoclonal antibodies. Said antibodies are designed for the diagnosis and/or treatment of VEGF-mediated disorders. The hybridomas, nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.
Status:
Application
Type:
Utility
Filling date:
31 Jan 2020
Issue date:
4 Jun 2020